These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 8075592)

  • 21. A phase II study of cyclophosphamide followed by PIXY321 as a means of mobilizing peripheral blood hematopoietic progenitor cells.
    Roman-Unfer S; Bitran JD; Garrison L; Proeschel C; Hanauer S; Schroeder L; Johnson L; Klein L; Martinec J
    Exp Hematol; 1996 Jun; 24(7):823-8. PubMed ID: 8647233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neutrophil maturation of CD34+ cells from peripheral blood and bone marrow in serum-free culture medium with PIXY321 and granulocyte-colony stimulating factor (G-CSF).
    Smith SL; Bender JG; Berger C; Lee WJ; Loudovaris M; Martinson JA; Opotowsky JD; Qiao X; Schneidkraut M; Sweeney P; Unverzagt KL; Van Epps DE; Williams DE; Williams SF; Zimmerman TM
    J Hematother; 1997 Aug; 6(4):323-34. PubMed ID: 9377071
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interleukin-3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GM-CSF): two cytokines increasing histamine synthesis by hematopoietic cells.
    Dy M; Schneider E
    Eur Cytokine Netw; 1991; 2(3):153-72. PubMed ID: 1716491
    [No Abstract]   [Full Text] [Related]  

  • 24. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
    Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
    Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of in vivo administration of IL-3 and IL-6, alone and in combination with G-CSF, GM-CSF or IL-1, on haematopoiesis, graft-versus-host disease and survival after murine haematopoietic stem cell transplantation.
    Atkinson K; Vos B; Kang-Er Z; Guiffre A; Seymour R; Gillis S
    Cytokines Mol Ther; 1995 Mar; 1(1):47-55. PubMed ID: 9384663
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simultaneous administration of TPO and G-CSF after cytoreductive treatment of rhesus monkeys prevents thrombocytopenia, accelerates platelet and red cell reconstitution, alleviates neutropenia, and promotes the recovery of immature bone marrow cells.
    Neelis KJ; Dubbelman YD; Qingliang L; Thomas GR; Eaton DL; Wagemaker G
    Exp Hematol; 1997 Sep; 25(10):1084-93. PubMed ID: 9293906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. pIXY321 protects against Ara-C or taxol-induced apoptosis and loss of clonogenic survival of normal human bone marrow progenitor cells.
    Bhalla K; Ibrado AM; Bradt JE; Ray S; Huang Y; Tang C; Nawabi A; Hoffman R
    Leukemia; 1995 Nov; 9(11):1851-6. PubMed ID: 7475274
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of granulocyte colony-stimulating factor in mobilization and transplantation of peripheral blood progenitor and stem cells .
    Haas R; Murea S
    Cytokines Mol Ther; 1995 Dec; 1(4):249-70. PubMed ID: 9384679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular modeling of the GM-CSF and IL-3 receptor complexes.
    Lyne PD; Bamborough P; Duncan D; Richards WG
    Protein Sci; 1995 Oct; 4(10):2223-33. PubMed ID: 8535258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antifungal effects of yeast-derived rhu-GM-CSF in patients receiving high-dose chemotherapy given with or without autologous stem cell transplantation: a retrospective analysis.
    Peters BG; Adkins DR; Harrison BR; Velasquez WS; Dunphy FR; Petruska PJ; Bowers CE; Niemeyer R; McIntyre W; Vrahnos D; Auberry SE; Spitzer G
    Bone Marrow Transplant; 1996 Jul; 18(1):93-102. PubMed ID: 8832001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Culture and characterization of hematopoietic progenitor cells from miniature swine.
    Emery DW; Sachs DH; LeGuern C
    Exp Hematol; 1996 Jul; 24(8):927-35. PubMed ID: 8690052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transcriptional regulation of the c-fms proto-oncogene mediated by granulocyte/macrophage colony-stimulating factor (GM-CSF) in murine cell lines.
    Helftenbein G; Krusekopf K; Just U; Cross M; Ostertag W; Niemann H; Tamura T
    Oncogene; 1996 Feb; 12(4):931-5. PubMed ID: 8632916
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ex vivo expansion of megakaryocyte progenitors: effect of various growth factor combinations on CD34+ progenitor cells from bone marrow and G-CSF-mobilized peripheral blood.
    Gehling UM; Ryder JW; Hogan CJ; Hami L; McNiece I; Franklin W; Williams S; Helm K; King J; Shpall EJ
    Exp Hematol; 1997 Oct; 25(11):1125-39. PubMed ID: 9328449
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Present and future clinical relevance of interleukin 3.
    Gianella-Borradori A
    Stem Cells; 1994; 12 Suppl 1():241-8. PubMed ID: 7696963
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential effect of erythropoietin and GM-CSF on megakaryocytopoiesis from primitive bone marrow cells in serum-free conditions.
    Cardier JE; Erickson-Miller CL; Murphy MJ
    Stem Cells; 1997; 15(4):286-90. PubMed ID: 9253112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
    Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transcription of genes encoding granulocyte-macrophage colony-stimulating factor, interleukin 3, and interleukin 6 receptors and lack of proliferative response to exogenous cytokines in nonhematopoietic human malignant cell lines.
    Guillaume T; Sekhavat M; Rubinstein DB; Hamdan O; Symann ML
    Cancer Res; 1993 Jul; 53(13):3139-44. PubMed ID: 8319222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of granulocyte-macrophage colony-stimulating factor in Philadelphia (Ph1)-positive acute lymphoblastic leukemia: studies on two newly established Ph1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181).
    Estrov Z; Talpaz M; Zipf TF; Kantarjian HM; Ku S; Ouspenskaia MV; Hirsch-Ginsberg C; Huh Y; Yee G; Kurzrock R
    J Cell Physiol; 1996 Mar; 166(3):618-30. PubMed ID: 8600166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro response of normal and aplastic anemia bone marrow to mast cell growth factor and in combination with granulocyte-macrophage colony-stimulating factor and interleukin-3.
    Gibson FM; Scopes J; Daly S; Ball SE; Gordon-Smith EC
    Exp Hematol; 1994 Mar; 22(3):302-12. PubMed ID: 8112428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma.
    Vadhan-Raj S; Papadopoulos NE; Burgess MA; Linke KA; Patel SR; Hays C; Arcenas A; Plager C; Kudelka AP; Hittelman WN
    J Clin Oncol; 1994 Apr; 12(4):715-24. PubMed ID: 8151315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.